OnKure Therapeutics (OKUR) to Release Quarterly Earnings on Monday

OnKure Therapeutics (NASDAQ:OKUR) is projected to announce its results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($1.15) per share for the quarter.

OnKure Therapeutics Trading Up 1.9%

Shares of NASDAQ:OKUR opened at $2.71 on Monday. OnKure Therapeutics has a 12 month low of $1.70 and a 12 month high of $5.60. The company has a 50-day moving average price of $2.75 and a 200 day moving average price of $2.83. The company has a market cap of $36.72 million, a price-to-earnings ratio of -0.57 and a beta of 0.45.

Hedge Funds Weigh In On OnKure Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. ADAR1 Capital Management LLC purchased a new stake in OnKure Therapeutics in the 4th quarter worth about $2,941,000. Shay Capital LLC grew its stake in shares of OnKure Therapeutics by 17.4% during the third quarter. Shay Capital LLC now owns 917,934 shares of the company’s stock valued at $2,524,000 after buying an additional 135,888 shares during the last quarter. Prosight Management LP raised its holdings in shares of OnKure Therapeutics by 204.9% in the fourth quarter. Prosight Management LP now owns 816,909 shares of the company’s stock worth $2,369,000 after buying an additional 548,950 shares during the period. Rosalind Advisors Inc. bought a new stake in shares of OnKure Therapeutics during the 4th quarter worth approximately $2,118,000. Finally, Renaissance Technologies LLC boosted its holdings in OnKure Therapeutics by 40.7% during the 4th quarter. Renaissance Technologies LLC now owns 247,350 shares of the company’s stock valued at $717,000 after acquiring an additional 71,600 shares during the period. 90.98% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of OnKure Therapeutics in a research report on Monday, December 22nd. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $32.00.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.